For research use only. Not for therapeutic Use.
<p style=/line-height:25px/>LM22A-4 is a specific agonist of tyrosine kinase receptor B.<br>IC50:<br>Target: Trk Receptor B<br>In vitro: LM22A-4 significantly up-regulates OPN and ALPase mRNA expression in a dose-dependent manner and OC mRNA level is significantly increased by 5 μM of LM22A-4. LM22A-4 significantly increases OPN, ALPase and OC mRNA expression in a time-dependent manner. LM22A-4 stimulated OPN and OC mRNA expression in HCEM cells cultured with mineralizing media[2].<br>In vivo: LM22A-4 (10 mg/kg, i.p.) significantly reduces the degree of tissue injury and apoptosis (TUNEL staining and caspase-3 and Bcl-2 expression) compared with vehicle treated group. LM22A-4 also significantly ameliorates the recovery of limb function. LM22A-4 (10 mg/kg) treatment results in a significant increase in neuron number. LM22A-4 administration (10 mg/kg) significantly improves the neurological scores compared with those of the solvent-treated animals[1].</p>
| Catalog Number | I003394 |
| CAS Number | 37988-18-4 |
| Synonyms | (1Z,3Z,5Z)-N/’1,N/’3,N/’5-tris(2-hydroxyethyl)benzene-1,3,5-tris(carboxylimidic acid) |
| Molecular Formula | C15H21N3O6 |
| Purity | ≥95% |
| Target | Protein Tyrosine Kinase/RTK |
| Solubility | DMSO: ≥ 29 mg/mL |
| Storage | Store at +4C |
| IUPAC Name | 1-N,3-N,5-N-tris(2-hydroxyethyl)benzene-1,3,5-tricarboxamide |
| InChI | InChI=1S/C15H21N3O6/c19-4-1-16-13(22)10-7-11(14(23)17-2-5-20)9-12(8-10)15(24)18-3-6-21/h7-9,19-21H,1-6H2,(H,16,22)(H,17,23)(H,18,24) |
| InChIKey | RGWJKANXFYJKHN-UHFFFAOYSA-N |
| SMILES | C1=C(C=C(C=C1C(=O)NCCO)C(=O)NCCO)C(=O)NCCO |
| Reference | <p style=/line-height:25px/> |
